

Tablica 10. Prvih 30 lijekova prema financijskoj potrošnji izraženo u eurima u 2023. godini, bolnička potrošnja

RBR	ATK	INN	UKUPNI IZNOS EUR
1	L01FF02	pembrolizumab	73.622.161
2	L01EL01	ibrutinib	21.098.642
3	L02BB04	enzalutamid	18.896.213
4	L01FF01	nivolumab	17.823.760
5	L01FF05	atezolizumab	17.099.951
6	L04AA36	okrelizumab	16.609.877
7	L01FG01	bevacizumab	15.619.748
8	L01FC01	daratumumab	15.309.458
9	J06BA02	imunoglobulini, humani, za i.v. primjenu	13.818.563
10	B05AA01	albumin, ljudski	13.419.677
11	M09AX10	risdiplam	12.336.156
12	L04AX04	lenalidomid	12.188.120
13	L01FD02	pertuzumab	12.109.084
14	L01EF02	ribociklib	11.040.927
15	L01XX52	venetoklaks	10.842.292
16	R07AX32	ivakaftor, tezakaftor i eleksakaftor	10.269.677
17	L04AB02	infliksimab	10.029.795
18	L01FD01	trastuzumab	9.737.441
19	B05BB01	elektroliti	8.814.280
20	L01EF01	palbociklib	7.947.464
21	L01FD03	trastuzumab emtanzin	7.691.472
22	L01FY01	pertuzumab i trastuzumab	7.600.487
23	L03AA13	pegfilgrastim	7.364.342
24	R07AX02	ivakaftor	7.212.961
25	L01FA01	rituksimab	6.756.755
26	L01XK01	olaparib	6.636.350
27	L02BB05	apalutamid	6.515.585
28	L01EF03	abemaciklib	6.413.153
29	L01FA03	obinutuzumab	6.044.603
30	L04AA43	ravulizumab	5.942.292